Clinical Scorecard: PFAS Bioaccumulation: The Biology of Forever

At a Glance

Key Highlights

• PFAS do not accumulate in fatty tissues as traditional models suggest.
• New models are needed to accurately assess long-term, low-level chronic exposures.
• The unidentified organofluorine fraction in biological samples is increasing and varies by gender and exposure level.

Guideline-Based Recommendations

Diagnosis

• Utilize advanced mass spectrometry techniques for accurate PFAS detection.

Management

• Develop new risk assessment models that account for PFAS bioaccumulation dynamics.

Monitoring & Follow-up

• Regularly assess PFAS levels in drinking water and consumer products.

Risks

• Chronic exposure to PFAS may lead to unidentified health impacts due to bioaccumulation.

Patient & Prescribing Data

Individuals in areas with known PFAS contamination.

Focus on understanding the full spectrum of PFAS compounds and their interactions in the body.

Clinical Best Practices

• Incorporate multidisciplinary approaches in PFAS research.
• Train future researchers to consider a broad range of contaminants beyond PFAS.

References

• PFAS Research Overview